Corticosteroids in the Management of Pregnant Patients With Coronavirus Disease (COVID-19)

Obstet Gynecol. 2020 Oct;136(4):823-826. doi: 10.1097/AOG.0000000000004103.


Recent evidence supports the use of an early, short course of glucocorticoids in patients with COVID-19 who require mechanical ventilation or oxygen support. As the number of coronavirus disease 2019 (COVID-19) cases continues to increase, the number of pregnant women with the disease is very likely to increase as well. Because pregnant women are at increased risk for hospitalization, intensive care unit admission, and mechanical ventilation support, obstetricians will be facing the dilemma of initiating maternal corticosteroid therapy while weighing its potential adverse effects on the fetus (or neonate if the patient is postpartum and breastfeeding). Our objective is to summarize the current evidence supporting steroid therapy in the management of patients with acute respiratory distress syndrome and COVID-19 and to elaborate on key modifications for the pregnant patient.

MeSH terms

  • Betacoronavirus / isolation & purification
  • COVID-19
  • Coronavirus Infections* / epidemiology
  • Coronavirus Infections* / therapy
  • Critical Care / methods*
  • Drug Monitoring / methods
  • Female
  • Fetal Organ Maturity / drug effects
  • Glucocorticoids* / classification
  • Glucocorticoids* / pharmacology
  • Humans
  • Infant, Newborn
  • Medication Therapy Management / standards*
  • Oxygen Inhalation Therapy / methods
  • Pandemics*
  • Pneumonia, Viral* / epidemiology
  • Pneumonia, Viral* / therapy
  • Pregnancy
  • Pregnancy Complications, Infectious* / epidemiology
  • Pregnancy Complications, Infectious* / therapy
  • Pregnancy Complications, Infectious* / virology
  • Respiration, Artificial / methods
  • Risk Assessment
  • SARS-CoV-2


  • Glucocorticoids